Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease
Journal of Clinical Investigation · 2024
DOI: 10.1172/jci169137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Ararat J Ablooglu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases, and. Hauptthemen laut MEDLINE: Nitric Oxide Synthase Type III, Capillary Leak Syndrome, Disease Models, Animal, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Clarkson disease, or monoclonal gammopathy–associated idiopathic systemic capillary leak syndrome (ISCLS), is a rare, relapsing-remitting disorder featuring the abrupt extravasation of fluids and proteins into peripheral tissues, which in turn leads to hypotensive shock, severe hemoconcentration, and hypoalbuminemia. The specific leakage factor(s) and pathways in ISCLS are unknown, and there is no effective treatment for acute flares. Here, we characterize an autonomous vascular endothelial defect in ISCLS that was recapitulated in patient-derived endothelial cells (ECs) in culture and in a mouse model of disease. ISCLS-derived ECs were functionally hyperresponsive to permeability-inducing factors like VEGF and histamine, in part due to increased endothelial nitric oxide synthase (eNOS) activity. eNOS blockade by administration of N (γ)-nitro-l-arginine methyl ester (l-NAME) ameliorated vascular leakage in an SJL/J mouse model of ISCLS induced by histamine or VEGF challenge. eNOS mislocalization and decreased protein phosphatase 2A (PP2A) expression may contribute to eNOS hyperactivation in ISCLS-derived ECs. Our findings provide mechanistic insights into microvascular barrier dysfunction in ISCLS and highlight a potential therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lung and Vascular Inflammation Section, Laboratory of Allergic Diseases, and.
- Integrative Data Sciences Section, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
- Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Nephrology, Departments of Internal Medicine and Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Förderung
- Intramural NIH HHS
- National Institutes of Health
Zitieren
APA
Ablooglu, A. J., Chen, W. S., Xie, Z., Desai, A., Paul, S., Lack, J. B., Scott, L. A., Eisch, A. R., Dudek, A. Z., Parikh, S. M., & Druey, K. M. (2024). Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease. Journal of Clinical Investigation. https://doi.org/10.1172/jci169137
Vancouver
Ablooglu AJ, Chen WS, Xie Z, Desai A, Paul S, Lack JB, et al. Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease. Journal of Clinical Investigation. 2024. doi:10.1172/jci169137
BibTeX
@article{Ablooglu2024,
author = {Ablooglu, Ararat J and Chen, Wei-Sheng and Xie, Zhihui and Desai, Abhishek and Paul, Subrata and Lack, Justin B and Scott, Linda A and Eisch, A Robin and Dudek, Arkadiusz Z and Parikh, Samir M and Druey, Kirk M},
title = {Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease},
journal = {Journal of Clinical Investigation},
year = {2024},
doi = {10.1172/jci169137}
}
EUVIMED